<![CDATA[Pathfinders in Biopharma]]>f1c5f9d4-36d2-589b-a71b-8150e0f51803Fri, 27 Feb 2026 01:22:35 +0000Captivate.fmRBC Capital Marketshttps://artwork.captivate.fm/116bc31d-280a-4d9c-b085-35536df7b990/6MJ-PBGROFtb3W_BUMMKPfOQ.pngPathfinders in BiopharmaRBC Capital MarketsRBC Capital MarketsPerspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.https://www.rbccm.com/en/gib/biopharmafalseepisodicnopodcastNo biotech bubble – but can the sector’s rally persist through 2026?No biotech bubble – but can the sector’s rally persist through 2026?Strong launches, positive sentiment, flowing capital, and favorable macro and policy indicators: the signals remain strong as the biotech sector enters 2026. Yet investors may need to search harder for opportunities this year, according to new RBC research. Brian Abrahams, Head of Global Healthcare Research, highlights some of the classes set for new breakthroughs, and points to the potential tripwires that lie ahead as biotech looks to continue its near-historic rally.

]]>Strong launches, positive sentiment, flowing capital, and favorable macro and policy indicators: the signals remain strong as the biotech sector enters 2026. Yet investors may need to search harder for opportunities this year, according to new RBC research. Brian Abrahams, Head of Global Healthcare Research, highlights some of the classes set for new breakthroughs, and points to the potential tripwires that lie ahead as biotech looks to continue its near-historic rally.

]]>4c26c6ba-facf-4fb8-a62a-c49a6284ec64Tue, 27 Jan 2026 08:00:00 -050013:14falsefull234342MindMed: Rethinking brain health with psychedelic therapyMindMed: Rethinking brain health with psychedelic therapyOver the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and strong financial backing. CEO Rob Barrow outlines the company's ambitious goals and the path to potentially transforming mental healthcare at RBC's Global Healthcare Conference.

]]>Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and strong financial backing. CEO Rob Barrow outlines the company's ambitious goals and the path to potentially transforming mental healthcare at RBC's Global Healthcare Conference.

]]>5d416eb6-79f7-492e-a42e-fc8ac331687aWed, 17 Sep 2025 08:00:00 -050011:58falsefull233332Funding the future of retinal health with EyepointFunding the future of retinal health with EyepointEyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.

]]>Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.

]]>8a27d093-4a28-4e3e-b536-5f89bf8fec27Wed, 03 Sep 2025 08:00:00 -050012:13falsefull234342How Blackstone Life Sciences is bridging the innovation gapHow Blackstone Life Sciences is bridging the innovation gapParis Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the life sciences ecosystem in three key ways: late-stage product financing (Collaboration) and new company creation (Ownership), and non-dilutive financing (Credit and Royalties). He explains how Blackstone is bridging the innovation funding gap through high-conviction partnerships with larger BioPharma and MedTech companies, and targeted investment in late-stage trials.

]]>Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the life sciences ecosystem in three key ways: late-stage product financing (Collaboration) and new company creation (Ownership), and non-dilutive financing (Credit and Royalties). He explains how Blackstone is bridging the innovation funding gap through high-conviction partnerships with larger BioPharma and MedTech companies, and targeted investment in late-stage trials.

]]>3bc8b4e1-d9b1-41e1-9bc0-f9b7bbd712c0Thu, 24 Jul 2025 08:00:00 -050020:59falsefull235352Compass trials mark a milestone moment for the psychedelics sectorCompass trials mark a milestone moment for the psychedelics sectorCompass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.

]]>Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.

]]>c3284849-45c3-44a5-a1f7-32f49319d4d5Mon, 21 Jul 2025 08:00:00 -050012:35falsefull236362Cidara’s pursuit of universal flu protection with a single doseCidara’s pursuit of universal flu protection with a single doseEvery year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. Cidara Therapeutics believes it may have a better alternative. President and CEO Jeff Stein explains how Cidara's laser-like focus on developing CD388, a single-dose antiviral targeting all flu strains, has brought the 40-person company on the verge of a public health breakthrough.

Cidara announces positive topline results from its phase 2b NAVIGATE trial evaluating CD388

President and CEO Jeff Stein Bio

]]>Every year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. Cidara Therapeutics believes it may have a better alternative. President and CEO Jeff Stein explains how Cidara's laser-like focus on developing CD388, a single-dose antiviral targeting all flu strains, has brought the 40-person company on the verge of a public health breakthrough.

Cidara announces positive topline results from its phase 2b NAVIGATE trial evaluating CD388

President and CEO Jeff Stein Bio

]]>304ba270-85ab-4e40-8e2f-4d27ad8d85f2Fri, 11 Jul 2025 09:00:00 -050012:11falsefull234342Ocular Therapeutix’ bold vision to redefine retinal disease treatmentOcular Therapeutix’ bold vision to redefine retinal disease treatmentPravin Dugel, CEO of Ocular Therapeutix provides insights into existing treatments and future product candidates for retinal diseases, underlining the unique challenges, opportunities and innovations in this evolving landscape.

www.ocutx.com

Pravin U. Dugel, MD Biography

]]>Pravin Dugel, CEO of Ocular Therapeutix provides insights into existing treatments and future product candidates for retinal diseases, underlining the unique challenges, opportunities and innovations in this evolving landscape.

www.ocutx.com

Pravin U. Dugel, MD Biography

]]>f9a838e9-2f1d-4859-a897-a9575270edb7Thu, 03 Jul 2025 08:00:00 -050024:52falsefull236362PTC Therapeutics: Building a durable company to benefit patientsPTC Therapeutics: Building a durable company to benefit patientsA surgeon in burns reconstruction, Matt Klein swapped the operating room for the equally high-pressure environment of drug development. In this episode of Pathfinders in Biopharma, he sets out the vision for the company he now leads, PTC Therapeutics – a pioneer in the field of RNA therapies, now powering towards profitability with treatment candidates for a host of rare diseases.

]]>A surgeon in burns reconstruction, Matt Klein swapped the operating room for the equally high-pressure environment of drug development. In this episode of Pathfinders in Biopharma, he sets out the vision for the company he now leads, PTC Therapeutics – a pioneer in the field of RNA therapies, now powering towards profitability with treatment candidates for a host of rare diseases.

]]>e4a62826-cc20-4833-924c-fa6dcf9c4f1eFri, 27 Jun 2025 08:00:00 -050014:01falsefull232322BioAge is translating insights from the science of aging into new medicinesBioAge is translating insights from the science of aging into new medicinesScott Neidhold, Director in RBC’s Life Sciences Investment Banking Practice, sits down with Kristen Fortney, CEO and Co-Founder of BioAge, for a deep dive into how her company is turning cutting-edge aging science into real therapeutic breakthroughs — and what it means for the future of biopharma.

]]>Scott Neidhold, Director in RBC’s Life Sciences Investment Banking Practice, sits down with Kristen Fortney, CEO and Co-Founder of BioAge, for a deep dive into how her company is turning cutting-edge aging science into real therapeutic breakthroughs — and what it means for the future of biopharma.

]]>609aa2f8-8959-432f-b6e7-7be5c2deec8eThu, 29 May 2025 09:00:00 -050019:32falsefull231312Uncertainty reigns, but opportunity persists for biotech’s 2025Uncertainty reigns, but opportunity persists for biotech’s 2025Universal wisdom had it that a Republican sweep in the U.S. election would favor biotech. Appointments to the new administration’s healthcare leadership make that far less certain. What effect will this and other factors have on the industry in 2025, and where are the breakthroughs likely to be found? Brian Abrahams, Head of Global Healthcare Research at RBC Capital Markets, looks ahead with in this episode of Pathfinders in Biotech.

]]>Universal wisdom had it that a Republican sweep in the U.S. election would favor biotech. Appointments to the new administration’s healthcare leadership make that far less certain. What effect will this and other factors have on the industry in 2025, and where are the breakthroughs likely to be found? Brian Abrahams, Head of Global Healthcare Research at RBC Capital Markets, looks ahead with in this episode of Pathfinders in Biotech.

]]>2aa27788-9f59-4216-8f8d-bdb64391540eFri, 07 Feb 2025 08:00:00 -050009:17falsefull230302Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market InvestmentsUnlocking Biotech’s Potential: Strategies for Navigating Public and Private Market InvestmentsInnovation is surging in the U.S biotechnology sector, so why are investors still fearful about committing? Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, is joined by fund founders Craig Gordon, MD, CEO and CIO at GordonMD® Global Investments LP and Srini Akkaraju, MD, PhD, Managing Partner at Samsara BioCapital, to analyze the prospects for a full return of capital to the sector.

]]>Innovation is surging in the U.S biotechnology sector, so why are investors still fearful about committing? Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, is joined by fund founders Craig Gordon, MD, CEO and CIO at GordonMD® Global Investments LP and Srini Akkaraju, MD, PhD, Managing Partner at Samsara BioCapital, to analyze the prospects for a full return of capital to the sector.

]]>8efc72b7-5033-4db9-8348-61eed12c64c9Fri, 22 Nov 2024 08:00:00 -050022:38falsefull229292Former Investor Who Chose Broadcasting Over Biotech ETFsFormer Investor Who Chose Broadcasting Over Biotech ETFsFormer biotech investor, Brad Loncar has pivoted his career from investing to reporting on the industry. Instead of serving the biotech bubble, he hopes to reach a wide audience with interest in science. Loncar explains why he switched careers and sets out his ambitions for his channel, Biotech TV.

]]>Former biotech investor, Brad Loncar has pivoted his career from investing to reporting on the industry. Instead of serving the biotech bubble, he hopes to reach a wide audience with interest in science. Loncar explains why he switched careers and sets out his ambitions for his channel, Biotech TV.

]]>eba3d1cb-8fe9-4084-880e-2811a4454ea3Mon, 30 Sep 2024 08:00:00 -050011:46falsefull228282Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery?Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery?The hardest parts of drug discovery will be vastly simplified if the mysteries of molecules and proteins can be cracked. That may be beyond human capabilities – but AI is working hard on it. In this episode of RBC’s Pathfinders in Biopharma, Noël Brown is joined by Clarissa Desjardins, CEO of Congruence, and Laksh Aithani, CEO and Co-founder of Charm Therapeutics, to discuss how far the tech can take us.

]]>The hardest parts of drug discovery will be vastly simplified if the mysteries of molecules and proteins can be cracked. That may be beyond human capabilities – but AI is working hard on it. In this episode of RBC’s Pathfinders in Biopharma, Noël Brown is joined by Clarissa Desjardins, CEO of Congruence, and Laksh Aithani, CEO and Co-founder of Charm Therapeutics, to discuss how far the tech can take us.

]]>010df606-f8a8-470e-ba5e-b91d29f1a365Thu, 29 Aug 2024 08:00:00 -050033:55falsefull229292Shots-on-Goal Licensing Company Aims for BreakthroughsShots-on-Goal Licensing Company Aims for BreakthroughsA very special breed of animals is helping biotech and pharma companies in the quest for new human therapeutics. CFO Kurt Gustafson joins Pathfinders in Biopharma to explain the technologies behind OmniAb’s business model.

]]>A very special breed of animals is helping biotech and pharma companies in the quest for new human therapeutics. CFO Kurt Gustafson joins Pathfinders in Biopharma to explain the technologies behind OmniAb’s business model.

]]>f6d92a1f-1ca7-4db9-9af3-e0a4aca8d971Fri, 19 Jul 2024 08:00:00 -050013:52falsefull229292Why Biopharma Needs to Tell Better Stories on Novel DrugsWhy Biopharma Needs to Tell Better Stories on Novel DrugsRonald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutics explains his ambitions for his company’s new antibody therapy and for the future of the industry. 

]]>Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutics explains his ambitions for his company’s new antibody therapy and for the future of the industry. 

]]>da18e7f8-c026-44b3-85e1-31b3c60f2e86Thu, 11 Jul 2024 09:00:00 -050015:31falsefull228282Venture capital velocity: What’s driving renewed momentum in biotech?Venture capital velocity: What’s driving renewed momentum in biotech?In biotech, a recovery is already well underway. Expected interest rate cuts and improving valuations across public and private markets are creating a compelling environment for deals, entrances, exits, and trades to take shape.

In this episode, biotech venture capital experts assess the sector’s sharper focus on funding fundamental science, evolving deal structures, including the return of reverse mergers and dual-track processes, and the key therapeutic modalities that are driving momentum in the market.

Hear from Andrew Aherrera, Partner at Panacea Venture; Jeni Lee, Partner at Pivotal Life Sciences; Regina Salvat, Principal at Sofinnova; and Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital Markets, as they share their fresh perspectives on the dynamic forces propelling the biotech industry forward.

]]>In biotech, a recovery is already well underway. Expected interest rate cuts and improving valuations across public and private markets are creating a compelling environment for deals, entrances, exits, and trades to take shape.

In this episode, biotech venture capital experts assess the sector’s sharper focus on funding fundamental science, evolving deal structures, including the return of reverse mergers and dual-track processes, and the key therapeutic modalities that are driving momentum in the market.

Hear from Andrew Aherrera, Partner at Panacea Venture; Jeni Lee, Partner at Pivotal Life Sciences; Regina Salvat, Principal at Sofinnova; and Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital Markets, as they share their fresh perspectives on the dynamic forces propelling the biotech industry forward.

]]>10f99098-8682-45ba-a820-0030949956daMon, 08 Jul 2024 08:00:00 -050035:03falsefull229292Pharma Understands Phase One Data – But Does the Market?Pharma Understands Phase One Data – But Does the Market?Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara Sullivan, explains the company’s journey to find the right investors, and why she believes the markets still have some learning to do when analyzing data from early-stage studies.

]]>Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara Sullivan, explains the company’s journey to find the right investors, and why she believes the markets still have some learning to do when analyzing data from early-stage studies.

]]>a93befe4-495c-44fa-93ed-abce25ca9055Fri, 21 Jun 2024 08:00:00 -050025:30falsefull227272Davern Capital sees GLP-1 Opportunities Beyond ObesityDavern Capital sees GLP-1 Opportunities Beyond ObesityDavern Capital’s founder, Elie Kobrin, approaches the biopharma market from a long/short perspective – but as a former doctor, he also speaks the language of medicine. He explains the fund’s approach and offers insights on hot topics in the current market.

]]>Davern Capital’s founder, Elie Kobrin, approaches the biopharma market from a long/short perspective – but as a former doctor, he also speaks the language of medicine. He explains the fund’s approach and offers insights on hot topics in the current market.

]]>5b4ef5eb-04f9-4921-82db-5e1d6b38021aFri, 14 Jun 2024 08:00:00 -050009:39falsefull226262Betting on Healthcare’s Future Hits – and MissesBetting on Healthcare’s Future Hits – and MissesAs a healthcare-focused, market-neutral investor, Vince Aita stays close to new product developments with a view to identifying future successes and failures. At RBC’s Global Healthcare Conference, he offered his insights on everything from the future of obesity innovation to the impact of the IRA.

]]>As a healthcare-focused, market-neutral investor, Vince Aita stays close to new product developments with a view to identifying future successes and failures. At RBC’s Global Healthcare Conference, he offered his insights on everything from the future of obesity innovation to the impact of the IRA.

]]>6cffaa3d-2c8e-4161-a2e4-9f937f104ed8Mon, 10 Jun 2024 08:00:00 -050014:47falsefull227272Innovation and an Aging Population Drive MedTechInnovation and an Aging Population Drive MedTechThe MedTech sector continues to grow in the U.S. as innovation in patient treatments and delivery meets increased demand from an aging population. Medical technology analyst Shagun Singh assesses key data points from the RBC Capital Markets’ Doctor Days events, looking at how the healthcare sector can empower investors to position themselves for future growth.

]]>The MedTech sector continues to grow in the U.S. as innovation in patient treatments and delivery meets increased demand from an aging population. Medical technology analyst Shagun Singh assesses key data points from the RBC Capital Markets’ Doctor Days events, looking at how the healthcare sector can empower investors to position themselves for future growth.

]]>9d3b23b1-e3fa-4bc2-aca3-85308dd96f3cWed, 05 Jun 2024 08:00:00 -050016:01falsefull225252Biopharma Investors See Opportunities in Targeted Treatments and Gene EditingBiopharma Investors See Opportunities in Targeted Treatments and Gene EditingPersonalized, targeted drugs and gene therapies are still at the forefront of medical innovation, as we discovered at RBC Capital Markets annual Doctor Days meetings. These insightful forums bring together key opinion leader clinicians and researchers from various therapeutic fields with institutional investors to discuss where opportunities lie, the next big breakthroughs, and the most novel drug therapies. Brian Abrahams, Gregory Renza, and Luca Issi join the podcast to discuss findings from the meetings.

]]>Personalized, targeted drugs and gene therapies are still at the forefront of medical innovation, as we discovered at RBC Capital Markets annual Doctor Days meetings. These insightful forums bring together key opinion leader clinicians and researchers from various therapeutic fields with institutional investors to discuss where opportunities lie, the next big breakthroughs, and the most novel drug therapies. Brian Abrahams, Gregory Renza, and Luca Issi join the podcast to discuss findings from the meetings.

]]>f2691209-37d9-4dab-91ce-16ffd8835a7dMon, 03 Jun 2024 08:00:00 -050020:39falsefull224242Biotech with a Mission to Target Unmet Cancer NeedsBiotech with a Mission to Target Unmet Cancer NeedsIDEAYA’s drug development programs center around addressing unmet patient needs. Its founder tells Pathfinders in Biopharma why he believes there has never been more opportunity for breakthroughs in the fight against cancer.

]]>IDEAYA’s drug development programs center around addressing unmet patient needs. Its founder tells Pathfinders in Biopharma why he believes there has never been more opportunity for breakthroughs in the fight against cancer.

]]>5244ed9e-e885-4b23-85e7-348af0f06bdeFri, 31 May 2024 09:00:00 -050013:37falsefull225252The M&A Pool Set to Accelerate Biotech InnovationThe M&A Pool Set to Accelerate Biotech InnovationQ1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC’s biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector’s future.

]]>Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC’s biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector’s future.

]]>1128af03-1c63-4760-a08e-1f4346357347Wed, 03 Apr 2024 08:00:00 -050013:51falsefull223232How PIPEs finally unblocked biotech’s funding flowsHow PIPEs finally unblocked biotech’s funding flowsThe first quarter of 2024 has seen biotech’s funding drought broken, largely through private investment in public equity (PIPE) deals. In this episode of Pathfinders in Biopharma, three members of RBC’s biotech investment banking team look at the impact of PIPEs’ success on the sector and consider how long it can last – and why it has not been universally welcomed.

]]>The first quarter of 2024 has seen biotech’s funding drought broken, largely through private investment in public equity (PIPE) deals. In this episode of Pathfinders in Biopharma, three members of RBC’s biotech investment banking team look at the impact of PIPEs’ success on the sector and consider how long it can last – and why it has not been universally welcomed.

]]>62b5238a-3998-431b-b609-a55cfe99ed34Fri, 29 Mar 2024 08:00:00 -050017:36falsefull222222Disruptive Forces in Healthcare: Why HCIT is finally set to bounce backDisruptive Forces in Healthcare: Why HCIT is finally set to bounce backU.S. healthcare desperately needs to cut costs and improve outcomes. There is no single solution, but three disruptive forces in the digital health space are speeding change – and adding up to a healthy outlook for HCIT. Sean Dodge, Healthcare Technology Analyst, joins the podcast to unpack some of his predictions on the most impactful forces affecting healthcare.

]]>U.S. healthcare desperately needs to cut costs and improve outcomes. There is no single solution, but three disruptive forces in the digital health space are speeding change – and adding up to a healthy outlook for HCIT. Sean Dodge, Healthcare Technology Analyst, joins the podcast to unpack some of his predictions on the most impactful forces affecting healthcare.

]]>eb309676-9998-4234-8525-b99c8b349bbcThu, 07 Mar 2024 08:00:00 -050012:58falsefull221212Will the Biotech Rebound Run into Pricing Policy Obstacles?Will the Biotech Rebound Run into Pricing Policy Obstacles?Drug pricing is already an issue in the U.S. election campaign. Brian Abrahams, MD and Head of Biotech Research at RBC Capital Markets joins the Pathfinders in Biopharma podcast to consider how this, together with other policy developments in the U.S. and worldwide, might affect a resurgent biotech sector.

]]>Drug pricing is already an issue in the U.S. election campaign. Brian Abrahams, MD and Head of Biotech Research at RBC Capital Markets joins the Pathfinders in Biopharma podcast to consider how this, together with other policy developments in the U.S. and worldwide, might affect a resurgent biotech sector.

]]>2000c386-77e6-4e4d-a3fc-330bc775c564Tue, 27 Feb 2024 08:00:00 -050013:25falsefull220202Few IPOs but plenty of follow-on for biotech in 2023Few IPOs but plenty of follow-on for biotech in 2023After a year of stark contrasts in the public and private equity markets for healthcare, 2024 is shaping up to be another mixed outlook. While biotech continues to bolster the market, albeit more in follow-on offerings than IPOs, and HCIT and healthcare services have tailwinds, the medtech and value-based care subsectors have challenges as well as opportunities. Join our Co-Heads of Healthcare Equity Markets for their insights into the year ahead.

]]>After a year of stark contrasts in the public and private equity markets for healthcare, 2024 is shaping up to be another mixed outlook. While biotech continues to bolster the market, albeit more in follow-on offerings than IPOs, and HCIT and healthcare services have tailwinds, the medtech and value-based care subsectors have challenges as well as opportunities. Join our Co-Heads of Healthcare Equity Markets for their insights into the year ahead.

]]>abffa8f0-1dc5-4f4b-a328-fac0a9859394Mon, 22 Jan 2024 08:00:00 -050023:35falsefull219192U.S. Outlook: Will the US economy achieve a soft landing in 2024?U.S. Outlook: Will the US economy achieve a soft landing in 2024?As the U.S. economy shows positive signs for growth, inflation, and interest rates in 2024, RBC Capital Markets’ RBC Capital Markets’ Michael Reid, Blake Gwinn, Vito Sperduto and Larry Grafstein analyze the challenges posed by consumer spending, political gridlock, and quantitative tightening. This episode was originally published on RBC's Strategic Alternatives podcast.

]]>As the U.S. economy shows positive signs for growth, inflation, and interest rates in 2024, RBC Capital Markets’ RBC Capital Markets’ Michael Reid, Blake Gwinn, Vito Sperduto and Larry Grafstein analyze the challenges posed by consumer spending, political gridlock, and quantitative tightening. This episode was originally published on RBC's Strategic Alternatives podcast.

]]>be714316-9bed-43b3-b46f-6964c713e88eFri, 29 Dec 2023 08:00:00 -050026:28falsefull218182Raising Venture Capital: A New Playbook for A New Era in BiotechRaising Venture Capital: A New Playbook for A New Era in BiotechIn an era characterized by macro headwinds and profound market volatility, the biotech industry continues to raise capital to fuel drug development, clinical trials, and innovation. Capital raising in challenging markets comes with additional risks, leading venture capital firms and crossover investors to identify creative, unconventional deal structures and strategies that are redefining the biotech investment landscape.

Join Chen Yu, Founder & Managing Partner at TCGX, Matthew Young, Managing Director at Longitude Capital, Arsani William, CIO & Managing Partner at Logos Capital, and RBC’s Noël Brown, Head of US Biotechnology Investment Banking, for a roundtable discussion exploring how investors across the biotech ecosystem are navigating market complexity to put dollars to work creatively to manage risks, maximize rewards, and stimulate growth.

]]>In an era characterized by macro headwinds and profound market volatility, the biotech industry continues to raise capital to fuel drug development, clinical trials, and innovation. Capital raising in challenging markets comes with additional risks, leading venture capital firms and crossover investors to identify creative, unconventional deal structures and strategies that are redefining the biotech investment landscape.

Join Chen Yu, Founder & Managing Partner at TCGX, Matthew Young, Managing Director at Longitude Capital, Arsani William, CIO & Managing Partner at Logos Capital, and RBC’s Noël Brown, Head of US Biotechnology Investment Banking, for a roundtable discussion exploring how investors across the biotech ecosystem are navigating market complexity to put dollars to work creatively to manage risks, maximize rewards, and stimulate growth.

]]>49d0941d-d33c-441c-8efc-6dbbc5f13237Wed, 22 Nov 2023 08:00:00 -050036:19falsefull217172ECM: Robust End to Year, Despite Previous VolatilityECM: Robust End to Year, Despite Previous VolatilityAs RBC Capital Markets looks forward to a robust end to the year, John Hoffman and Jason Levitz, Co-Heads of Healthcare Equity Capital Markets explore how the firms who succeed in an especially dynamic market will be those willing to embrace new ways of thinking about unlocking value.

]]>As RBC Capital Markets looks forward to a robust end to the year, John Hoffman and Jason Levitz, Co-Heads of Healthcare Equity Capital Markets explore how the firms who succeed in an especially dynamic market will be those willing to embrace new ways of thinking about unlocking value.

]]>d4d2f155-2f97-43b0-ad17-dbd88ab4a935Tue, 31 Oct 2023 08:00:00 -050031:24falsefull216162Biotech Halftime Report: A Winding Road AheadBiotech Halftime Report: A Winding Road AheadJoin Head of US Capital Markets Research, Mark Odendahl and biotech analysts Brian Abrahams and Gregory Renza, as they explore the dynamic biotech sector landscape in H2 2023.

This episode was originally broadcast on Industries in Motion, the RBC podcast.

]]>Join Head of US Capital Markets Research, Mark Odendahl and biotech analysts Brian Abrahams and Gregory Renza, as they explore the dynamic biotech sector landscape in H2 2023.

This episode was originally broadcast on Industries in Motion, the RBC podcast.

]]>e5ce1b12-f137-4f55-ad33-9af7f40b3e11Tue, 26 Sep 2023 08:00:00 -050017:26falsefull215152The Urgent Need to Address the Youth Mental Health LandscapeThe Urgent Need to Address the Youth Mental Health LandscapeU.S. soccer legends and World Cup champions Briana Scurry and Dr. Sara Hess joined Andrew Callaway, Global Head of Healthcare Investment Banking at RBC Capital Markets, at this year’s RBC Global Healthcare Conference.

]]>U.S. soccer legends and World Cup champions Briana Scurry and Dr. Sara Hess joined Andrew Callaway, Global Head of Healthcare Investment Banking at RBC Capital Markets, at this year’s RBC Global Healthcare Conference.

]]>154caf4f-c17f-4ec8-ac55-0e2609362cbaThu, 17 Aug 2023 08:00:00 -050028:06falsefull214142Website Traffic Reveals Biopharma Sales TrendsWebsite Traffic Reveals Biopharma Sales TrendsA new RBC ElementsTM report, “Insights from the BioWeb,” looks at the predictive potential of website traffic as a means to uncover underappreciated market trends and sales insights. Mark Odendahl, Head of US Capital Markets Research, is joined by Brian Abrahams, Head of Biotechnology at RBC Capital Markets, to discuss the report’s findings. 

]]>A new RBC ElementsTM report, “Insights from the BioWeb,” looks at the predictive potential of website traffic as a means to uncover underappreciated market trends and sales insights. Mark Odendahl, Head of US Capital Markets Research, is joined by Brian Abrahams, Head of Biotechnology at RBC Capital Markets, to discuss the report’s findings. 

]]>04e6efa7-fa14-48a2-89d7-afaf11eba03fMon, 07 Aug 2023 08:00:00 -050010:39falsefull213132When to Call it Quits: VCs Making Tough Decisions in a Tough MarketWhen to Call it Quits: VCs Making Tough Decisions in a Tough MarketWhile the public biotech markets remain volatile, VCs continue to raise new funds. Are we witnessing a renaissance in the private capital markets? The bankruptcy rate of biotechs is historically among the lowest of US publicly traded companies, however, companies are failing and there is still a widely held belief that too many biotech companies are in existence today. What are the hallmarks of companies that will not make it, and when does it make sense to ‘call it’ or divest?

In this episode of Pathfinders in Biopharma, hear from Jerel Davis, Managing Director at Versant Ventures, Otello Stampacchia, Founder & Managing Director at Omega Funds, Simeon George, CEO & Managing Partner at SR One and RBC’s Noël Brown, Head of US Biotechnology Investment Banking, for a roundtable discussion on navigating the path to growth.

]]>While the public biotech markets remain volatile, VCs continue to raise new funds. Are we witnessing a renaissance in the private capital markets? The bankruptcy rate of biotechs is historically among the lowest of US publicly traded companies, however, companies are failing and there is still a widely held belief that too many biotech companies are in existence today. What are the hallmarks of companies that will not make it, and when does it make sense to ‘call it’ or divest?

In this episode of Pathfinders in Biopharma, hear from Jerel Davis, Managing Director at Versant Ventures, Otello Stampacchia, Founder & Managing Director at Omega Funds, Simeon George, CEO & Managing Partner at SR One and RBC’s Noël Brown, Head of US Biotechnology Investment Banking, for a roundtable discussion on navigating the path to growth.

]]>6be8d8d2-dd71-4db8-9eb5-51e118aafdc0Thu, 13 Jul 2023 08:00:00 -050032:02falsefull212122How Biotech M&A is Redefining the Strategic LandscapeHow Biotech M&A is Redefining the Strategic LandscapeGiven current macro and regulatory headwinds, determining the optimal time to sell a biotech company is a multifaceted decision that requires careful consideration of several key factors. Hear from industry veterans Ted Love, Marc de Garidel, and Abbas Kazimi who share their insights on a new era of M&A in a panel moderated by RBC Capital Markets Analysts Dr. Brian Abrahams, Dr. Luca Issi and Dr. Gregory Renza.

]]>Given current macro and regulatory headwinds, determining the optimal time to sell a biotech company is a multifaceted decision that requires careful consideration of several key factors. Hear from industry veterans Ted Love, Marc de Garidel, and Abbas Kazimi who share their insights on a new era of M&A in a panel moderated by RBC Capital Markets Analysts Dr. Brian Abrahams, Dr. Luca Issi and Dr. Gregory Renza.

]]>df820231-7f86-4d98-8f22-101bf1af1da8Fri, 23 Jun 2023 08:00:00 -050025:53falsefull211112Healthcare Should Get Ready for ‘Fast and Furious’ M&AHealthcare Should Get Ready for ‘Fast and Furious’ M&AHear from Vito Sperduto, RBC’s Co-Head of Global M&A, and his panel of RBC Capital Markets’ expert bankers on how large healthcare firms with strong balance sheets are putting cash to work — driving a ‘fast and furious’ surge of M&A activity in the second half of the year and into 2024. Learn why healthcare momentum is building and how smaller deals are shaping M&A across the sector in the latest episode of Pathfinders in Biopharma.

This podcast also features insights from Andrew ‘Cal’ Callaway, Global Head of Healthcare Investment Banking, Ahmed Attia, Managing Director of Healthcare M&A, and Co-Head of US M&A, David Levin.

This podcast episode was originally broadcast on Strategic Alternatives, the RBC M&A podcast.

]]>Hear from Vito Sperduto, RBC’s Co-Head of Global M&A, and his panel of RBC Capital Markets’ expert bankers on how large healthcare firms with strong balance sheets are putting cash to work — driving a ‘fast and furious’ surge of M&A activity in the second half of the year and into 2024. Learn why healthcare momentum is building and how smaller deals are shaping M&A across the sector in the latest episode of Pathfinders in Biopharma.

This podcast also features insights from Andrew ‘Cal’ Callaway, Global Head of Healthcare Investment Banking, Ahmed Attia, Managing Director of Healthcare M&A, and Co-Head of US M&A, David Levin.

This podcast episode was originally broadcast on Strategic Alternatives, the RBC M&A podcast.

]]>64a7be99-cccf-48cd-8227-339647e54d75Thu, 08 Jun 2023 08:00:00 -050026:06falsefull210102Innovation and Growth: Key Ingredients to Healthcare M&AInnovation and Growth: Key Ingredients to Healthcare M&ACompressed valuations, heightened CEO confidence, and the desire to accelerate top-line growth and scale innovation are the key factors driving healthcare M&A in 2023. As deal activity starts to accelerate, our banking experts are asking, what’s next for the sector? Listen to Pathfinders in Biopharma to find out.

This episode features insights from Vito Sperduto, Co-Head of Global M&A, Andrew ‘Cal’ Callaway, Global Head of Healthcare Investment Banking, Ahmed Attia, Managing Director of Healthcare M&A, and David Levin, Co-Head of US M&A at RBC Capital Markets.

This episode was originally broadcast on Strategic Alternatives, the RBC M&A podcast.

]]>Compressed valuations, heightened CEO confidence, and the desire to accelerate top-line growth and scale innovation are the key factors driving healthcare M&A in 2023. As deal activity starts to accelerate, our banking experts are asking, what’s next for the sector? Listen to Pathfinders in Biopharma to find out.

This episode features insights from Vito Sperduto, Co-Head of Global M&A, Andrew ‘Cal’ Callaway, Global Head of Healthcare Investment Banking, Ahmed Attia, Managing Director of Healthcare M&A, and David Levin, Co-Head of US M&A at RBC Capital Markets.

This episode was originally broadcast on Strategic Alternatives, the RBC M&A podcast.

]]>f105d857-dc3f-492d-a73b-7b0017530c3cWed, 07 Jun 2023 08:00:00 -050024:18falsefull2992Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market.

]]>In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market.

]]>25675f1a-ca1b-44a9-919d-3294f4077c2cFri, 02 Jun 2023 08:00:00 -050017:04falsefull2882Global Blood Therapeutics Commitment to Sickle-Cell InnovationGlobal Blood Therapeutics Commitment to Sickle-Cell InnovationIn this rebroadcast episode, we flash back to a previous interview with Dr. Ted W. Love, President and CEO of Global Blood Therapeutics (GBT). Dr. Love spoke with our biotechnology analyst Gregory Renza about GBT’s mission-driven culture which led to the development of Oxbryta, the company’s breakthrough sickle-cell treatment, as well as the specific challenges the company faced in tackling a rare orphan disease.

GBT was acquired by Pfizer in October 2022, reinforcing their commitment to sick cell disease and continuing to build on their 30-year legacy in the rare hematology space.

]]>In this rebroadcast episode, we flash back to a previous interview with Dr. Ted W. Love, President and CEO of Global Blood Therapeutics (GBT). Dr. Love spoke with our biotechnology analyst Gregory Renza about GBT’s mission-driven culture which led to the development of Oxbryta, the company’s breakthrough sickle-cell treatment, as well as the specific challenges the company faced in tackling a rare orphan disease.

GBT was acquired by Pfizer in October 2022, reinforcing their commitment to sick cell disease and continuing to build on their 30-year legacy in the rare hematology space.

]]>e1bc10c5-a5dd-425f-9263-65309b929988Mon, 22 May 2023 08:00:00 -050022:29falsefull2772Is This the Breakthrough Moment for Genetic Medicine?Is This the Breakthrough Moment for Genetic Medicine?Genetic medicine is poised to unlock more value for patients and investors due to disruptive technologies like mRNA, siRNA and gene editing. With an estimated 27 genetic medicines already approved, RBC’s biotechnology analyst Luca Issi explains how these technologies could be used next, and why companies able to combine the right choice of intervention with strong execution may stand to benefit most.

]]>Genetic medicine is poised to unlock more value for patients and investors due to disruptive technologies like mRNA, siRNA and gene editing. With an estimated 27 genetic medicines already approved, RBC’s biotechnology analyst Luca Issi explains how these technologies could be used next, and why companies able to combine the right choice of intervention with strong execution may stand to benefit most.

]]>4b30431e-f035-44f2-950d-abdb8bae5e96Thu, 13 Apr 2023 08:00:00 -050017:25falsefull2662The Hidden Revolution Set to Turn US Healthcare on its HeadThe Hidden Revolution Set to Turn US Healthcare on its HeadIn the latest episode of Pathfinders, our Healthcare technology analyst Sean Dodge explores a quiet but accelerating revolution in the way US healthcare works – and the new breed of companies poised to benefit.

]]>In the latest episode of Pathfinders, our Healthcare technology analyst Sean Dodge explores a quiet but accelerating revolution in the way US healthcare works – and the new breed of companies poised to benefit.

]]>2b03c5a0-8320-4212-9a68-8c0f43446aabThu, 26 Jan 2023 08:00:00 -050019:07falsefull2552The Big Picture for BiotechThe Big Picture for BiotechIn this latest episode, our head of biotech research Brian Abrahams shares a big picture analysis of the industry, outlining the long-term disruptions and opportunities ahead for biotech.

]]>In this latest episode, our head of biotech research Brian Abrahams shares a big picture analysis of the industry, outlining the long-term disruptions and opportunities ahead for biotech.

]]>6d4d30cc-f718-4d10-acf1-f6c8f649405dTue, 13 Dec 2022 05:15:00 -050021:49falsefull2442Why Biopharma Investment Requires a Different MindsetWhy Biopharma Investment Requires a Different MindsetIn the latest episode of Pathfinders, Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital Markets, reveals why he’s feeling optimistic about M&A in biopharma and how leading in biotech investment and corporates needs visionary long-term thinking.

]]>In the latest episode of Pathfinders, Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital Markets, reveals why he’s feeling optimistic about M&A in biopharma and how leading in biotech investment and corporates needs visionary long-term thinking.

]]>77e167c3-7512-4e5c-8a47-7cf8161ca6a8Tue, 22 Nov 2022 05:30:00 -050022:52falsefull2332The Optimism Behind the Biopharma MarketThe Optimism Behind the Biopharma MarketIn this episode, Dr. Chen Yu, Founder and Managing Partner at TCG X and Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, discuss why they remain optimistic about biotech and what’s happening behind the scenes in public and private markets.

]]>In this episode, Dr. Chen Yu, Founder and Managing Partner at TCG X and Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, discuss why they remain optimistic about biotech and what’s happening behind the scenes in public and private markets.

]]>9475d102-7bd9-4d54-bc1c-44af390b2694Mon, 03 Oct 2022 00:45:00 -050025:49falsefull2222Biotech Investors: How to Find Value in a Bear MarketBiotech Investors: How to Find Value in a Bear MarketHow are top investors navigating the longest biotech bear market in almost 20 years? RBC Capital Markets Healthcare Desk Sector Strategist Chris McCarthy talks to HealthCor’s Ben Snedeker and Omega Funds founder Otello Stampacchia to find out.

]]>How are top investors navigating the longest biotech bear market in almost 20 years? RBC Capital Markets Healthcare Desk Sector Strategist Chris McCarthy talks to HealthCor’s Ben Snedeker and Omega Funds founder Otello Stampacchia to find out.

]]>316a79ff-4f7c-4aae-a1c0-1c0fd38696c3Mon, 21 Mar 2022 13:03:00 -050028:55falsefull2112A call to action: Global Blood Therapeutics on tackling orphan diseaseA call to action: Global Blood Therapeutics on tackling orphan diseaseWhat does it take to tackle the most perplexing orphan diseases? Ted W. Love, M.D., President and CEO, Global Blood Therapeutics (GBT), speaks with RBC Capital Markets’ Senior Biotechnology Analyst Gregory Renza, M.D., about having a mission and the drive to succeed on this episode of Pathfinders.

]]>What does it take to tackle the most perplexing orphan diseases? Ted W. Love, M.D., President and CEO, Global Blood Therapeutics (GBT), speaks with RBC Capital Markets’ Senior Biotechnology Analyst Gregory Renza, M.D., about having a mission and the drive to succeed on this episode of Pathfinders.

]]>9c9cadb8-7773-47b9-9126-4a03aae7506bWed, 08 Dec 2021 13:17:00 -050027:33falsefull110101Ionis: Raising The Bar For ESGIonis: Raising The Bar For ESGIn this episode of Pathfinders, Luca Issi, Senior Biotech Analyst at RBC Capital Markets, speaks with Beth Hougen, CFO of Ionis – a leading innovator in the development of antisense medicines and RNA-targeted therapeutics – to find out how the firm is embedding ESG into its vision, strategy and performance.

]]>In this episode of Pathfinders, Luca Issi, Senior Biotech Analyst at RBC Capital Markets, speaks with Beth Hougen, CFO of Ionis – a leading innovator in the development of antisense medicines and RNA-targeted therapeutics – to find out how the firm is embedding ESG into its vision, strategy and performance.

]]>f1e86ea5-72bf-47a4-8cb1-9524d73a2d59Thu, 28 Oct 2021 10:41:00 -050023:46falsefull1991Biotech and Big Pharma: Blueprint for Successful PartnershipBiotech and Big Pharma: Blueprint for Successful PartnershipAs biotech firms and large pharma companies find new synergies to bring new treatments to market together, Noël Brown, Managing Director and Head of US Biotechnology Investment Banking at RBC Capital Markets, interviews pharma industry veteran, now Biopharma Managing Director, Greg Wiederrecht on what it takes to ensure a strategic partnership not only survives, but thrives.

]]>As biotech firms and large pharma companies find new synergies to bring new treatments to market together, Noël Brown, Managing Director and Head of US Biotechnology Investment Banking at RBC Capital Markets, interviews pharma industry veteran, now Biopharma Managing Director, Greg Wiederrecht on what it takes to ensure a strategic partnership not only survives, but thrives.

]]>42ee74cf-c166-41c7-97a8-626e27fa639cThu, 30 Sep 2021 16:12:00 -050023:11falsefull1881What’s Material in ESG for Biopharma Firms?What’s Material in ESG for Biopharma Firms?For biopharma companies, ESG commitments can look considerably different from other sectors. We spoke with the team of ESG leads at Gilead Sciences to understand the five key components driving its ESG strategy, how it’s evolved and how it impacts their business. 

]]>For biopharma companies, ESG commitments can look considerably different from other sectors. We spoke with the team of ESG leads at Gilead Sciences to understand the five key components driving its ESG strategy, how it’s evolved and how it impacts their business. 

]]>e9ceaac6-1ad6-48b3-8f7c-758f4c8d183cTue, 04 May 2021 17:43:00 -050018:32falsefull1771Inside Track: Behind the Scenes of a Major Biotech SPACInside Track: Behind the Scenes of a Major Biotech SPACRBC Capital Markets’ Noël Brown, Head of US Biotech Investment Banking, goes behind the scenes of one of the biggest biotech SPAC deals of the year with NuvationBio Founder and CEO, Dr. David Hung and Omega Funds Partner and President of its Omega Alpha SPAC, Michelle Doig. These two industry leaders at the cutting edge of biotech innovation and venture capital share how they brought NuvationBio’s public market vision to fruition on the latest episode of RBC’s Pathfinders podcast.

]]>RBC Capital Markets’ Noël Brown, Head of US Biotech Investment Banking, goes behind the scenes of one of the biggest biotech SPAC deals of the year with NuvationBio Founder and CEO, Dr. David Hung and Omega Funds Partner and President of its Omega Alpha SPAC, Michelle Doig. These two industry leaders at the cutting edge of biotech innovation and venture capital share how they brought NuvationBio’s public market vision to fruition on the latest episode of RBC’s Pathfinders podcast.

]]>c3cdcbe0-e633-423a-b0e8-0b6fa1a19dfaMon, 26 Apr 2021 16:40:00 -050023:48falsefull1661Biotech SPACs: A new route to going publicBiotech SPACs: A new route to going publicAs more firms and investors look to SPACs as an IPO alternative, will this change the way biotech companies access public markets long-term? Our investment banking team goes inside the SPAC boom to explain what companies need to know before choosing their path to going public.

]]>As more firms and investors look to SPACs as an IPO alternative, will this change the way biotech companies access public markets long-term? Our investment banking team goes inside the SPAC boom to explain what companies need to know before choosing their path to going public.

]]>e2863578-2ff3-4523-8c38-bd00dfa08c39Fri, 12 Mar 2021 17:09:00 -050030:22falsefull15515AM Ventures: Fueling the Next Generation of Innovators5AM Ventures: Fueling the Next Generation of InnovatorsIn this episode of Pathfinders, Brian Abrahams, Managing Director and Co-Head of Biotechnology Equity Research at RBC Capital Markets speaks with Andy Schwab, Co-Founder and Managing Partner at 5AM Ventures.

Key Points

  • Prescription Digital Therapeutics will be vital to future treatment
  • Unlocking microbiome could lead to better disease management

]]>In this episode of Pathfinders, Brian Abrahams, Managing Director and Co-Head of Biotechnology Equity Research at RBC Capital Markets speaks with Andy Schwab, Co-Founder and Managing Partner at 5AM Ventures.

Key Points

  • Prescription Digital Therapeutics will be vital to future treatment
  • Unlocking microbiome could lead to better disease management

]]>bd80d019-6e4a-4b05-ae6e-15b6cec54685Mon, 21 Dec 2020 01:15:00 -050019:14falsefull1441Vida Ventures: Powering Breakthroughs in BiopharmaVida Ventures: Powering Breakthroughs in BiopharmaLuca Issi, Senior Biotechnology Research Analyst at RBC Capital Markets, discusses the art of building biopharma breakthroughs with Arjun Goyal, Co-Founder and Managing Director of Vida Ventures.

Key Points

  • Maturation of the industry is increasing innovation and capital inflows
  • Strong science, management and investors can keep the IPO window open

]]>Luca Issi, Senior Biotechnology Research Analyst at RBC Capital Markets, discusses the art of building biopharma breakthroughs with Arjun Goyal, Co-Founder and Managing Director of Vida Ventures.

Key Points

  • Maturation of the industry is increasing innovation and capital inflows
  • Strong science, management and investors can keep the IPO window open

]]>712113b8-ede6-4d63-9492-3dd8b563ae3fMon, 21 Dec 2020 01:15:00 -050022:57falsefull1331Biotech IPOs: Navigating the New LandscapeBiotech IPOs: Navigating the New LandscapeEven in a boom, many biotech executives may be unprepared for the risks involved in undertaking an IPO. Noël Brown and Tim Papp, Managing Directors focused on biotechnology in our Global Healthcare Investment Banking and Jason Levitz, Head of Healthcare Equity Capital Markets at RBC Capital Markets discuss the right steps to take, and the pitfalls to avoid, in today’s markets.

]]>Even in a boom, many biotech executives may be unprepared for the risks involved in undertaking an IPO. Noël Brown and Tim Papp, Managing Directors focused on biotechnology in our Global Healthcare Investment Banking and Jason Levitz, Head of Healthcare Equity Capital Markets at RBC Capital Markets discuss the right steps to take, and the pitfalls to avoid, in today’s markets.

]]>d9be0feb-ab56-4c77-83fc-09cb854de224Thu, 10 Dec 2020 09:45:00 -050020:00falsefull1221Biotech IPOs: New Steps to Success on the Road to Going PublicBiotech IPOs: New Steps to Success on the Road to Going PublicIn our launch edition of Pathfinders, we look at the best practices to follow on the road to IPO and the new predictive factors for success in today’s buoyant biopharma markets.

]]>In our launch edition of Pathfinders, we look at the best practices to follow on the road to IPO and the new predictive factors for success in today’s buoyant biopharma markets.

]]>3f6e6d85-d777-40d0-8449-9fca2fcc4c13Tue, 01 Dec 2020 23:45:00 -050022:40falsefull1111